Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVID trial of enoxaparin for ambulatory COVID-19
2020-005624-10Phase 3Terminated
- Sponsor
- University Hospital Zurich
- Start
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enoxaparin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University Hospital Zurich. Primary endpoint: Primary efficacy outcome. Started Mar 2021; status: terminated.
02
Drugs
enoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005624-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005624-10.